Analysis

Entera Bio Ltd. (ENTX) Stock Analysis

Entera Bio Ltd. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to ENTX.

websiteENTX/analysis/ENTX

Entera Bio Ltd.

Entera Bio Ltd. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to ENTX.

Stock profile

Ticker

ENTX

Asset type

Stock

Market cap

$59.6M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Entera Bio Ltd. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • ENTX primary listing
  • A2JQXP
  • 5DT

Latest Entera Bio Ltd. news

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Developm...

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity a...

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1...

The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 202...

Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation...

TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multipl...

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incr...

Research sections

Valuation

Review valuation context for Entera Bio Ltd..

Future growth

Review future growth context for Entera Bio Ltd..

Past performance

Review past performance context for Entera Bio Ltd..

Financial health

Review financial health context for Entera Bio Ltd..

Dividend

Review dividend context for Entera Bio Ltd..

Management

Review management context for Entera Bio Ltd..

Ownership

Review ownership context for Entera Bio Ltd..

Other information

Review other information context for Entera Bio Ltd..

Community

Review community context for Entera Bio Ltd..